These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

384 related items for PubMed ID: 26030651

  • 1. Short and Long-Term Effects of the Angiotensin II Receptor Blocker Irbesartan on Intradialytic Central Hemodynamics: A Randomized Double-Blind Placebo-Controlled One-Year Intervention Trial (the SAFIR Study).
    Peters CD, Kjaergaard KD, Jensen JD, Christensen KL, Strandhave C, Tietze IN, Novosel MK, Bibby BM, Jespersen B.
    PLoS One; 2015; 10(6):e0126882. PubMed ID: 26030651
    [Abstract] [Full Text] [Related]

  • 2. High-sensitivity Troponin T in hemodialysis patients: a randomized placebo-controlled sub-study investigating angiotensin-II-blockade, variation over time and associations with clinical outcome.
    Peters CD, Kjaergaard KD, Christensen KL, Bibby BM, Jespersen B, Jensen JD.
    BMC Nephrol; 2020 Oct 28; 21(1):452. PubMed ID: 33115436
    [Abstract] [Full Text] [Related]

  • 3. Angiotensin blockade and progressive loss of kidney function in hemodialysis patients: a randomized controlled trial.
    Kjaergaard KD, Peters CD, Jespersen B, Tietze IN, Madsen JK, Pedersen BB, Novosel MK, Laursen KS, Bibby BM, Strandhave C, Jensen JD.
    Am J Kidney Dis; 2014 Dec 28; 64(6):892-901. PubMed ID: 25011693
    [Abstract] [Full Text] [Related]

  • 4. No significant effect of angiotensin II receptor blockade on intermediate cardiovascular end points in hemodialysis patients.
    Peters CD, Kjaergaard KD, Jensen JD, Christensen KL, Strandhave C, Tietze IN, Novosel MK, Bibby BM, Jensen LT, Sloth E, Jespersen B.
    Kidney Int; 2014 Sep 28; 86(3):625-37. PubMed ID: 24670413
    [Abstract] [Full Text] [Related]

  • 5. Renal and cardiovascular effects of irbesartan in dialysis patients--a randomized controlled trial protocol (SAFIR study).
    Peters CD, Kjærgaard KD, Jespersen B, Christensen KL, Jensen JD.
    Dan Med J; 2013 Apr 28; 60(4):A4602. PubMed ID: 23651713
    [Abstract] [Full Text] [Related]

  • 6. Long-term effects of angiotensin II blockade with irbesartan on inflammatory markers in hemodialysis patients: A randomized double blind placebo controlled trial (SAFIR study).
    Peters CD, Kjaergaard KD, Nielsen CH, Christensen KL, Bibby BM, Jensen JD, Jespersen B.
    Hemodial Int; 2017 Jan 28; 21(1):47-62. PubMed ID: 27346437
    [Abstract] [Full Text] [Related]

  • 7. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
    Derosa G, Cicero AF, D'Angelo A, Fogari E, Salvadeo S, Gravina A, Ferrari I, Fassi R, Fogari R.
    Clin Ther; 2007 Apr 28; 29(4):602-10. PubMed ID: 17617283
    [Abstract] [Full Text] [Related]

  • 8. Acute renal effects of AT1-receptor blockade after exogenous angiotensin II infusion in healthy subjects.
    Schmitt F, Martinez F, Brillet G, Nguyen-Khoa T, Brouard R, Sissmann J, Lacour B, Grunfeld JP.
    J Cardiovasc Pharmacol; 1998 Feb 28; 31(2):314-21. PubMed ID: 9475275
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effect of angiotensin receptor blockade on central haemodynamics in essential hypertension: results of a randomised trial.
    Schneider MP, Delles C, Klingbeil AU, Ludwig M, Kolloch RE, Krekler M, Stumpe KO, Schmieder RE.
    J Renin Angiotensin Aldosterone Syst; 2008 Mar 28; 9(1):49-56. PubMed ID: 18404609
    [Abstract] [Full Text] [Related]

  • 11. Efficacy, safety and tolerability of valsartan 80 mg compared to irbesartan 150 mg in hypertensive patients on long-term hemodialysis (VALID study).
    Leidig M, Bambauer R, Kirchertz EJ, Szabã T, Handrock R, Leinung D, Baier M, Schmieder RE.
    Clin Nephrol; 2008 Jun 28; 69(6):425-32. PubMed ID: 18538118
    [Abstract] [Full Text] [Related]

  • 12. Improved insulin sensitivity by the angiotensin receptor antagonist irbesartan in patients with systolic heart failure: a randomized double-blinded placebo-controlled study.
    Doehner W, Todorovic J, Kennecke C, Rauchhaus M, Sandek A, Lainscak M, van Linthout S, Tschöpe C, von Haehling S, Anker SD.
    Int J Cardiol; 2012 Nov 29; 161(3):137-42. PubMed ID: 21856022
    [Abstract] [Full Text] [Related]

  • 13. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients.
    Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP.
    Circulation; 2005 Mar 01; 111(8):1012-8. PubMed ID: 15723979
    [Abstract] [Full Text] [Related]

  • 14. Twenty-four-hour ambulatory blood pressure evaluation of antihypertensive agents.
    Zanchetti A.
    J Hypertens Suppl; 1997 Dec 01; 15(7):S21-5. PubMed ID: 9532517
    [Abstract] [Full Text] [Related]

  • 15. Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects.
    Burnier M, Hagman M, Nussberger J, Biollaz J, Armagnac C, Brouard R, Weber B, Brunner HR.
    Hypertension; 1995 Apr 01; 25(4 Pt 1):602-9. PubMed ID: 7721404
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.
    Lee SE, Kim YJ, Lee HY, Yang HM, Park CG, Kim JJ, Kim SK, Rhee MY, Oh BH, Investigators.
    Clin Ther; 2012 Mar 01; 34(3):552-568, 568.e1-9. PubMed ID: 22381711
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Inhibition of the acute effects of angiotensin II by the receptor antagonist irbesartan in normotensive men.
    Ribstein J, Picard A, Armagnac C, Sissmann J, Mimran A.
    J Cardiovasc Pharmacol; 2001 Apr 01; 37(4):449-60. PubMed ID: 11300658
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.